In light of the recent tragic news regarding the outbreak of fungal meningitis, the origin of which is suspected contaminated vials of methylprednisolone acetate suspension compounded by the New England Compounding Center, Geisinger-Lewistown Hospital confirmed today that the hospital pharmacy has never contracted with the New England Compounding Center in Massachusetts to provide compounded products for the hospital or the pain management center.
“Geisinger-Lewistown Hospital has not contracted with anyone for the compounding of sterile methylprednisolone acetate preservative free injection. This is the implicated agent responsible for the outbreak,” said Kay Hamilton, President and CEO of Geisinger-Lewistown Hospital. “We take our commitment to patient safety very seriously and have procedures in place to assure the highest quality of care possible.”
Geisinger-Lewistown Hospital goes through an extensive review of any prospective pharmaceutical product supplier. All current contracted suppliers for Geisinger-Lewistown Hospital are registered with the FDA, meet or exceed USP Chapter 797 standards, and meet cGMP requirements.
In addition, any product selected for use in a patient is thoroughly examined for any potential problems and defects prior to administration. “We take every measure to assure that patients are receiving a safe drug,” noted Richard Stomackin, Director of Pharmacy Services at the hospital.
For questions and more information, call (717) 242-7102.